UroGen Pharma
UroGen Pharma's revenue rose 21.4% to $110 million in fiscal 2025. Its operating margin was −113.7%, down from −107.1% a year earlier. Free cash flow was −$163 million. The diluted share count rose 12.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What UroGen Pharma does
UroGen is a biotechnology company that develops and sells treatments for urothelial and specialty cancers, such as cancers of the lining of the bladder and upper urinary tract. Its technology is RTGel, a gel that is liquid when cold and turns to a gel at body temperature, so a drug stays in the urinary tract for several hours.
It has two approved products, both made of the drug mitomycin in RTGel. Jelmyto treats low-grade upper tract urothelial cancer. Zusduri treats recurrent low-grade intermediate risk non-muscle invasive bladder cancer. Both are designed to destroy tumors without surgery. It earns money by selling them.
It is also working on UGN-501, an investigational virus designed to attack cancer cells. It has a loan from Pharmakon, and under a prepaid forward contract it owes tiered cash payments to RTW based on net sales of its products.
Its biggest risks, as it describes them
- Needing more financing, and diluting shareholders or giving up rights to its technology if it raises it.
- Depending heavily on the success of its two approved products, Jelmyto and Zusduri.
- Debt from its loan with Pharmakon and covenants under its RTW contract that limit extra borrowing.
- Results for its drugs in larger, broader groups of patients that may differ from its clinical studies.
- Raising money may force it to cut back operations or give up product rights.
Income statement
UroGen Pharma lost money in fiscal 2025: a net loss of $154 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 67 | 100 | 142 | 242 | 120 |
| Debt incl. finance leases | 0 | 98 | 99 | 124 | 130 |
| Net debt (negative means net cash) | −67 | −2 | −42 | −118 | 9 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 5.1x | 5.4x | 5.4x | 6.0x | 4.0x |
| Quick ratio | 4.9x | 5.2x | 5.2x | 5.8x | 3.6x |
Cash flow
Projections
Project UroGen Pharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought UroGen Pharma shares on the open market, and 2 insiders sold $4.7 million, $1.3 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Jason Drew SmithGeneral Counsel | Sold | 1,519 | $42.54 | $64,618 | Form 4 |
| Sep 8, 2026 | Mark SchoenbergChief Medical Officer | Sold | 871 | $42.92 | $37,383 | Form 4 |
| Aug 20, 2026 | Mark SchoenbergChief Medical Officer | Sold | 60,677 | $47.05 | $2.9 million | Form 4 |
| Jul 9, 2026 | Mark SchoenbergChief Medical Officer | Sold plan | 10,000 | $40.00 | $400,000 | Form 4 |
| Jun 22, 2026 | Mark SchoenbergChief Medical Officer | Sold plan | 10,000 | $35.01 | $350,100 | Form 4 |
| Jun 8, 2026 | Mark SchoenbergChief Medical Officer | Sold | 5,222 | $27.30 | $142,561 | Form 4 |
| May 8, 2026 | Mark SchoenbergChief Medical Officer | Sold plan | 10,000 | $30.00 | $300,000 | Form 4 |
| Feb 3, 2026 | Jason Drew SmithGeneral Counsel | Sold | 7,479 | $19.69 | $147,262 | Form 4 |
| Feb 3, 2026 | Mark SchoenbergChief Medical Officer | Sold | 7,373 | $19.69 | $145,174 | Form 4 |
| Nov 19, 2025 | Mark SchoenbergChief Medical Officer | Sold plan | 10,000 | $25.00 | $250,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 5 of 9 | 2 of 9 |
| Rule of 40 | −64.0% | −98.1% | −126.8% |
| Altman Z'' | −10.10 | −6.22 | −15.59 |
| Accruals ratio | −16.5% | −13.0% | 3.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 6 of 9 | 5 of 9 | 2 of 9 |
Compare
Put UroGen Pharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| UroGen Pharma | FY25 | 21.4% | −113.7% | −148.2% | — | — | 2 | |
| Zevra Therapeutics | FY25 | 350.9% | −59.1% | −2.3% | −218.8% | — | 5 | Compare |
| Zymeworks | FY25 | 38.9% | −87.3% | −32.6% | — | — | — | Compare |
| Nurix Therapeutics | FY25 | 54.0% | −340.2% | −313.7% | — | — | — | Compare |
| Eton Pharmaceuticals | FY25 | 104.9% | −1.1% | 12.8% | −1.9% | 1.4x | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 18 | 8 | 1 | 0 | 12 | 48 | 64 | 83 | 90 | 110 |
| Revenue growth | — | −53.5% | −86.2% | −98.4% | 65,450.0% | 307.2% | 34.0% | 28.5% | 9.3% | 21.4% |
| Gross profit | 18 | 8 | −1 | 0 | 11 | 43 | 57 | 73 | 82 | 97 |
| Research and development | — | 19 | 37 | 49 | 47 | 48 | 53 | 46 | 57 | 67 |
| Operating income | 1 | −20 | −77 | −110 | −127 | −92 | −79 | −66 | −97 | −125 |
| Net income | −2 | −20 | −76 | −105 | −128 | −111 | −110 | −102 | −127 | −154 |
| Diluted EPS (US$) | −1.91 | −2.14 | −4.80 | −5.12 | −5.90 | −4.96 | — | — | — | — |
| Diluted shares (millions) | 2 | 10 | 16 | 20 | 22 | 22 | 23 | 29 | 43 | 48 |
| Cash flow | ||||||||||
| Cash from operations | 4 | −10 | −37 | −71 | −106 | −85 | −88 | −76 | −97 | −162 |
| Capital expenditure | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | 3 | −10 | −38 | −71 | −107 | −86 | −88 | −77 | −97 | −163 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 6 | 31 | 30 | 28 | 23 | 11 | 9 | 13 | 12 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 21 | 73 | — | 147 | 102 | 67 | 100 | 142 | 242 | 120 |
| Debt incl. finance leases | — | — | — | — | — | 0 | 98 | 99 | 124 | 130 |
| Total assets | 23 | 76 | 104 | 202 | 122 | 120 | 136 | 178 | 286 | 200 |
| Total liabilities | 7 | 7 | 14 | 22 | 26 | 111 | 225 | 244 | 294 | 306 |
| Shareholders' equity | 16 | 68 | 90 | 180 | 96 | 8 | −89 | −65 | −9 | −106 |
| Margins and ratios | ||||||||||
| Gross margin | 99.8% | 92.7% | −59.8% | 100.0% | 91.5% | 89.3% | 88.1% | 88.7% | 90.2% | 88.7% |
| Operating margin | 4.5% | −244.6% | −6,842.2% | −608,211.1% | −1,074.2% | −192.1% | −122.8% | −79.2% | −107.1% | −113.7% |
| Net margin | −11.1% | −245.2% | −6,707.2% | −584,144.4% | −1,088.9% | −230.7% | −170.6% | −123.6% | −140.3% | −139.8% |
| Free cash flow margin | 19.9% | −120.6% | −3,359.4% | −396,344.4% | −907.7% | −178.3% | −136.4% | −92.6% | −107.4% | −148.2% |
| Rule of 40 (growth + FCF margin) | — | −174.1% | −3,445.6% | −396,442.8% | 64,542.3% | 128.9% | −102.5% | −64.0% | −98.1% | −126.8% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −47.2% | −95.4% | −77.8% | −92.9% | −211.6% | — | — | — | — |
| Return on assets | — | −40.6% | −84.5% | −68.7% | −79.2% | −91.7% | −86.0% | −65.1% | −54.7% | −63.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |